Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CR-001
001 · 1 trial · 1 indication
Per cohort
Per Cohort
Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
| Arm | Type | Description |
|---|---|---|
| CR-001 Dose escalation | EXPERIMENTAL | Escalating dose levels of CR-001 to define the maximum tolerated dose of CR-001 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable |
| CR-001 Backfill | EXPERIMENTAL | Escalating dose levels of CR-001 Indication-specific cohort populations will be tested |
| CR-001 Dose Optimization Cohort X | EXPERIMENTAL | monotherapy dose level (DL)-X Indication-specific cohort populations will be tested |
| CR-001 Dose Optimization Cohort Y | EXPERIMENTAL | monotherapy DL-Y Indication-specific cohort populations will be tested |
| Name | Type | Description |
|---|---|---|
| CR-001 | DRUG | Intravenous Infusion |
Key Inclusion Criteria * Life expectancy ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Adequate organ function and hematologic reserve based on laboratory parameters * Have measurable disease defined by RECIST v1.1 * For Backfill and Dose Optimization: W...
CR-001 is an investigational small molecule being developed for the treatment of locally advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CR-001 targets PD-1, a protein involved in immune checkpoint regulation. By targeting PD-1, CR-001 is designed to modulate the immune system's response to cancer cells, though its exact mechanism is still under investigation in clinical trials.
CR-001 is being developed by Crescent Biopharma, Inc., a company traded under the ticker CBIO. The drug is currently in Phase 1 clinical trials for locally advanced or metastatic solid tumors.
CR-001 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is recruiting participants with locally advanced or metastatic solid tumors.
CR-001 is being evaluated in a Phase 1 clinical trial with the identifier NCT07335497. This trial is recruiting adult participants with locally advanced or metastatic solid tumors and is being conducted in the United States, Australia, Ireland, Italy, Romania, South Korea, and Spain.
Yes, CR-001 is also known as -001. Both names refer to the same investigational drug being developed by Crescent Biopharma, Inc. for the treatment of locally advanced or metastatic solid tumors.